Simpler Grants.gov #RFA-DK-27-303

NIH Kidney Precision Medicine Project Central Hub Cooperative Agreement

The National Institutes of Health (NIH) is soliciting applications for the Kidney Precision Medicine Project (KPMP) Central Hub Cooperative Agreement. - Government Buyer: - National Institutes of Health (NIH) - Scope of Work: - Provide scientific, infrastructure, quality control, project management, and administrative support for the KPMP Central Hub - Collect and de-identify clinical data and samples from participants with acute kidney injury (AKI) or chronic kidney disease (CKD) - Collaborate with Recruitment Sites, Tissue Interrogation Sites, and the Kidney Tissue Atlas Coordinating Center - Create a Kidney Tissue Atlas, define disease subgroups, and identify critical cells, interstitial components, pathways, and therapeutic targets - Funding and Structure: - Cooperative agreement with estimated program funding of $5,000,000 - Products/Services Requested: - No specific products or OEMs requested; opportunity is for research support and scientific/administrative services - Unique Requirements: - Centralized coordination and quality control across multiple research sites - Data de-identification and secure management - Integration of clinical and tissue data for advanced kidney disease research - Place of Performance: - National Institutes of Health (federal office)

Description

This Notice of Funding Opportunity (NOFO) requests applications for the Kidney Precision Medicine Project (KPMP) - Central Hub (CH) to support the KPMP cohort, collect and de-identify all existing and new clinical data and samples, and provide scientific, infrastructure, quality control, project management, and administrative support. The CH will collaborate with the Recruitment Sites, Tissue Interrogation Sites, and Kidney Tissue Atlas Coordinating Center to obtain and evaluate kidney biopsies from participants with acute kidney injury or chronic kidney disease, create a Kidney Tissue Atlas, define disease subgroups, and identify critical cells, interstitial components, pathways, and targets for novel therapies. The funding instrument type is a cooperative agreement with an estimated program funding of $5,000,000. The estimated application due date is October 5, 2026, with an estimated project start date of July 1, 2027.

View original listing